Cationic Antimicrobial Peptides Are Leading the Way to Combat Oropathogenic Infections

Lin, Bruce; Li, Rong; Handley, Thomas N. G.; Wade, John D.; Li, Wenyi; O'Brien-Simpson, Neil M

doi:10.1021/acsinfecdis.1c00424

Cited by 27 publications

(27 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many important prospects for the approved AMPs by the US FDA are used in clinical applications, such as ophthalmology, dental, wound healing, and surgical infection ( Izadi et al, 2020 ). Several AMPs have shown tremendous therapeutic potential against various infectious diseases caused by pathogenic bacteria, including peptide ZXR-2 (FKIGGFIKKLWRSLLA) against pathogenic bacteria of dental caries, Porphyromonas gingivalis , Streptococcus sobrinus , Streptococcus mutans , and peptide PAC-113 (Clinical trial identifier: NCT00659971) as effective antimicrobial agents against oral candidiasis ( Chen et al, 2017 ; Sztukowska et al, 2019 ; Lin et al, 2021 ). Also, the results of several AMPs studies including in vivo and clinical trials have indicated the good therapeutic potential in treating various surgical infections and wound healing.…”

Section: Current Progress Of Amps In Medical Applicationsmentioning

confidence: 99%

Targeting Multidrug Resistance With Antimicrobial Peptide-Decorated Nanoparticles and Polymers

Dizaj

Salatin²,

Khezri³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

As a category of small peptides frequently found in nature, antimicrobial peptides (AMPs) constitute a major part of the innate immune system of various organisms. Antimicrobial peptides feature various inhibitory effects against fungi, bacteria, viruses, and parasites. Due to the increasing concerns of antibiotic resistance among microorganisms, development of antimicrobial peptides is an emerging tool as a favorable applicability prospect in food, medicine, aquaculture, animal husbandry, and agriculture. This review presents the latest research progress made in the field of antimicrobial peptides, such as their mechanism of action, classification, application status, design techniques, and a review on decoration of nanoparticles and polymers with AMPs that are used in treating multidrug resistance. Lastly, we will highlight recent progress in antiviral peptides to treat emerging viral diseases (e.g., anti-coronavirus peptides) and discuss the outlook of AMP applications.

show abstract

Section: Current Progress Of Amps In Medical Applicationsmentioning

confidence: 99%

Targeting Multidrug Resistance With Antimicrobial Peptide-Decorated Nanoparticles and Polymers

Dizaj

Salatin²,

Khezri³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Suspensions of multi-species of facultative anaerobic bacteria (FAB) including Actinomyces naeslundii, Streptococcus mutans and Streptococcus sanguinis or obligate anaerobic bacteria (OAB) including Parvimonas micra, Veillonella parvula and Fusobacterium nucleatum were subjected to concentration ranges of LL-37 and LfcinH. Compared to LfcinH, prominent inhibitory threshold concentrations of LL-37 were noticed (p < 0.0001) but the biofilm mass was also decreased better by LL-37 compared to LfcinH, highlighting the scope of LL-37 as a better AMP [168,169].…”

Section: Antimicrobial Peptidesmentioning

confidence: 99%

Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance

et al. 2022

View full text Add to dashboard Cite

A biofilm is a community of stable microorganisms encapsulated in an extracellular matrix produced by themselves. Many types of microorganisms that are found on living hosts or in the environment can form biofilms. These include pathogenic bacteria that can serve as a reservoir for persistent infections, and are culpable for leading to a broad spectrum of chronic illnesses and emergence of antibiotic resistance making them difficult to be treated. The absence of biofilm-targeting antibiotics in the drug discovery pipeline indicates an unmet opportunity for designing new biofilm inhibitors as antimicrobial agents using various strategies and targeting distinct stages of biofilm formation. The strategies available to control biofilm formation include targeting the enzymes and proteins specific to the microorganism and those involved in the adhesion pathways leading to formation of resistant biofilms. This review primarily focuses on the recent strategies and advances responsible for identifying a myriad of antibiofilm agents and their mechanism of biofilm inhibition, including extracellular polymeric substance synthesis inhibitors, adhesion inhibitors, quorum sensing inhibitors, efflux pump inhibitors, and cyclic diguanylate inhibitors. Furthermore, we present the structure–activity relationships (SAR) of these agents, including recently discovered biofilm inhibitors, nature-derived bioactive scaffolds, synthetic small molecules, antimicrobial peptides, bioactive compounds isolated from fungi, non-proteinogenic amino acids and antibiotics. We hope to fuel interest and focus research efforts on the development of agents targeting the uniquely complex, physical and chemical heterogeneous biofilms through a multipronged approach and combinatorial therapeutics for a more effective control and management of biofilms across diseases.

show abstract

“…[61] This mechanism of action has meant that AMPs do not readily induce resistance and are highly effective against antibiotic-susceptible and multi-drug-resistant bacteria [62] in both nosocomial and uropathogenic pathogens. [63] This attractive characteristic has inspired that the incorporation of AMPs can become a major research focus in preventing or reducing the growth of bacteria and biofilms. [64][65][66][67] Thus, AMPs have emerged as alternatives to routinely used antibiotics and are now being considered a new class of antimicrobial surface coatings.…”

Section: Polymer-based Dental Implantsmentioning

confidence: 99%

The overview of antimicrobial peptide‐coated implants against oral bacterial infections

Sun

et al. 2023

Aggregate

Self Cite

View full text Add to dashboard Cite

Dental implants are the most common therapeutic approach for resolving tooth loss and damage. Despite technical advances in treatment, implant failure rates can be as high as 23% with the major cause of peri-implantitis: a multi-species bacterial infection. With an annual growth rate in implant placements of 8.78% per annum, implant failure caused by bacterial infection is a significant oral and general health issue. The rise in antibiotic resistance in oral bacteria further adds pressure to implant failure; thus, there is a need for adjunctive therapy to improve implant outcomes. Due to the broad spectrum of activity and a low risk of inducing bacterial resistance, peptide antibiotics are emerging as a promising implant coating material to reduce/prevent peri-implantitis and improve dental implant success rates. In this review, we summarised the current strategies of coating antimicrobial peptides (AMPs) onto dental implant material surfaces with multi-functional properties to enhance osteoblast growth and prevent bacterial infections. This review compared the recent reported literature on dental implant coating with AMPs, which will provide an overview of the current dental implant coating strategies using AMPs and insights for future clinical applications.

show abstract

Cationic Antimicrobial Peptides Are Leading the Way to Combat Oropathogenic Infections

Cited by 27 publications

References 132 publications

Targeting Multidrug Resistance With Antimicrobial Peptide-Decorated Nanoparticles and Polymers

Targeting Multidrug Resistance With Antimicrobial Peptide-Decorated Nanoparticles and Polymers

Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance

The overview of antimicrobial peptide‐coated implants against oral bacterial infections

Contact Info

Product

Resources

About